A Phase 2,Multi-center, Open-label Study Evaluating Safety and Efficacy of Jaktinib Hydrochloride Tablets in Intermediate-risk and High-risk Myelofibrosis.
Latest Information Update: 19 Jan 2024
At a glance
- Drugs Gecaxitinib hydrochloride (Primary)
- Indications Myelofibrosis
- Focus Therapeutic Use
- Sponsors Suzhou Zelgen Biopharmaceuticals
Most Recent Events
- 12 Dec 2023 Results (At the data cutoff of June 30, 2022) assessing Efficacy, Safety, and Survival Findings after Long-Term Follow-up from ZGJAK002 for Myelofibrosis presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 11 Dec 2023 According to a Zelgen media release, results from this trial were presented at the 65th American Society of Hematology (ASH) Annual Meeting 2023.
- 11 Dec 2023 Long-term follow-up results presented in the Zelgen Media Release.